Intelligent Bio Solutions Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Harry Simeonidis
- Full Time Employees
- 58
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 142 West 57th Street New York City NY United States of America 10036
- IPO Date
- Dec 23, 2020
- CIK
- 0001725430
- Website
- ibs.inc
- Similar Companies
- Business
- Intelligent Bio Solutions Inc. operates as a medical technology enterprise, pioneering rapid, non-invasive testing solutions. The company's flagship offering is its Intelligent Fingerprinting Drug Screening System, which revolutionizes portable drug testing by analyzing sweat from fingertips. This innovative system quickly identifies recent use of substances like opiates, cocaine, methamphetamine, and cannabis, delivering results typically within ten minutes. This hygienic and cost-effective approach offers a significant alternative to traditional testing methods, eliminating biohazardous waste and privacy concerns while enhancing efficiency for users. The company strategically targets safety-critical industries such as construction, logistics, and manufacturing, along with drug treatment organizations and law enforcement. Its revenue model is largely driven by recurring sales of high-margin consumable cartridges, reflecting a "razor-razorblade" business strategy that has led to consistent growth. In pursuit of expanding its market presence, the company submitted a 510(k) premarket notification for its drug screening system to the U.S. Food and Drug Administration in late 2024, although the process has since evolved to a request for a new resubmission due to its novel nature. Intelligent Bio Solutions has achieved record quarterly revenues and significantly expanded its global footprint, now serving over 480 active customer accounts across more than 24 countries. Established in 2016 and headquartered in New York, New York, Intelligent Bio Solutions Inc., formerly known as GBS Inc. until its name change in October 2022, continues to advance its biosensor platform with potential for broader diagnostic applications across various medical indications.
Company News
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules
BlackRock Inc. Invests $149.96 Million in Intelligent Bio Solutions Inc. $INBS
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification
Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System
Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission
Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System
Comparing Eurofins Scient (OTCMKTS:ERFSF) & Intelligent Bio Solutions (NASDAQ:INBS)
Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18
Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
Comparing Establishment Labs (NASDAQ:ESTA) & Intelligent Bio Solutions (NASDAQ:INBS)
Aeon Global Health (OTCMKTS:AGHC) vs. Intelligent Bio Solutions (NASDAQ:INBS) Head-To-Head Review
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results